Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALZN 
Alzamend Neuro Inc (ALZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ALZN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45
1 Year Target Price $45
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.83% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.63M USD | Price to earnings Ratio - | 1Y Target Price 45 |
Price to earnings Ratio - | 1Y Target Price 45 | ||
Volume (30-day avg) 2 | Beta -0.32 | 52 Weeks Range 2.06 - 23.22 | Updated Date 08/29/2025 |
52 Weeks Range 2.06 - 23.22 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -101.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -107.38% | Return on Equity (TTM) -657.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7554528 | Price to Sales(TTM) - |
Enterprise Value 7554528 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.13 | Shares Outstanding 3139860 | Shares Floating 2880617 |
Shares Outstanding 3139860 | Shares Floating 2880617 | ||
Percent Insiders 0.81 | Percent Institutions 0.07 |
Upturn AI SWOT
Alzamend Neuro Inc
Company Overview
History and Background
Alzamend Neuro, Inc., formerly Milton Bank Capital, was founded in 2015. It focuses on developing novel pharmaceutical products for the treatment of neurodegenerative diseases and psychiatric disorders. Their primary focus is on developing treatments for Alzheimer's disease.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of new pharmaceutical treatments for neurodegenerative and psychiatric diseases, specifically Alzheimer's disease.
Leadership and Structure
Dr. Milton C. Ault III is the Chairman and Chief Executive Officer. The company has a board of directors and a scientific advisory board guiding its research and development efforts.
Top Products and Market Share
Key Offerings
- AL001: AL001 is an ionic cocrystal composition of lithium orotate. It's being developed as a treatment for Alzheimer's disease, bipolar disorder, post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). Alzamend Neuro is currently conducting clinical trials. Competitors in the Alzheimer's market include Biogen (with Aduhelm), Eisai, and Eli Lilly.
- AL002: AL002 is a cell-based therapeutic vaccine that seeks to stimulate the immune system to remove toxic beta-amyloid plaque. It is in preclinical stage. Competitors in the Alzheimer's vaccine space include Vaxxinity and AC Immune.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet needs, significant research and development costs, and a complex regulatory landscape. Alzheimer's disease represents a substantial market opportunity due to the aging population and the lack of effective treatments.
Positioning
Alzamend Neuro is a clinical-stage biopharmaceutical company. Its competitive advantage hinges on the potential efficacy and safety of its novel treatments and vaccines. The company is in early stages compared to competitors with approved drugs.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions USD by 2030s. Alzamend is attempting to capture a slice of this market through its development of AL001 and AL002.
Upturn SWOT Analysis
Strengths
- Novel drug candidates (AL001 and AL002)
- Focus on high-unmet-need areas (Alzheimer's)
- Strong scientific advisory board
Weaknesses
- Limited financial resources
- Early stage of development (high risk)
- Dependence on successful clinical trials
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Government grants and funding
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- BIIB
- ESAIY
- LLY
Competitive Landscape
Alzamend Neuro operates in a competitive landscape with established pharmaceutical companies. Its success depends on differentiating its products through improved efficacy, safety, or delivery methods.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development activities, not revenue generation.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and potential commercialization of AL001 and AL002. Analyst estimates are highly speculative due to the early stage of development.
Recent Initiatives: Recent initiatives include progressing AL001 through clinical trials and advancing AL002 toward clinical development.
Summary
Alzamend Neuro is a high-risk, high-reward clinical-stage biopharmaceutical company focused on Alzheimer's disease. The success of the company heavily relies on the positive outcomes of their ongoing clinical trials and their ability to secure funding to continue their research and development efforts. Their AL001 and AL002 drug candidates provide hope for future growth, but also are faced with fierce competition with already established pharmaceutical companies. Alzamend needs to overcome substantial regulatory and financial hurdles to succeed in this field.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, and industry reports.
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Information is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alzamend Neuro Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2021-06-15 | CEO & Director Mr. Stephan Jackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.alzamend.com |
Full time employees 4 | Website https://www.alzamend.com | ||
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.